UBS lowered the firm’s price target on Enhabit (EHAB) to $8.50 from $10 and keeps a Neutral rating on the shares. Enhabit’s Q2 results were largely positive, but the company is focused on combating the home health rate cut, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHAB: